A<unk>  (MTB) is a dedicated group of medical experts to evaluate hard-to-treat cancers and provide a personalized healthcare opportunity. It has also been called a Sequencing<unk><unk>  and it is characterized by the in-depth application of molecular analysis (e.g. genomics and transcriptomics) for a single patient.<unk> s are considered most useful for cancer types for which therapies are not effective, for example, in the case of heterogeneous sarcomas. The<unk> s are composed by clinical oncologists and pathologists alongside other specialists, which vary from institution to institution, but might include geneticists, bioinformaticians and molecular biologists. MTBs are considered to improve clinical outcomes for patients with<unk> s with unique molecular profiles.<unk> s have been used by a number of institutions, like the Dartmouth–Hitchcock Medical Center, the Johns Hopkins Hospital and the Moffitt Cancer Center.
Molecular tumor board
Molecular oncology
Cytotechnology
Cancer genome sequencing
Tissue bank
Imaging and Radiation Oncology Core
Lineage markers
Cancer Research UK